Umbilical stem cells dubbed 'Holy Grail' for regenerative medicine

Umbilical stem cells from Wharton's Jelly offer non-invasive, scalable regenerative therapy options.

Why it matters

  • Non-invasive and scalable stem cell source
  • Potential for wide-ranging medical applications

By the numbers

  • Cited study shows 31% decrease in ALS progression

The big picture

  • Only one FDA-approved MSC therapy exists currently
  • Could expand regenerative medicine if proven effective

What they're saying

  • Expert skepticism due to past trial failures
  • Patient hope for new treatment options

Caveats

  • Review of existing studies, not new data
  • Past MSC trials often failed in late stages

What’s next

  • More trials to confirm benefits and safety
  • Research on combining with biomaterials